2011年8月10日,

2011年8月10日,Wouter跺脚诊断,独家上周我们报道mChip的成功" HIV和梅毒测试在第一现场试验。对于一些进一步的信息,我们有联系塞缪尔·k .新航副教授哥伦比亚大学生物医学工程系,谁是本研究的主要研究人员之一。他的实验室专注于为全球健康诊断和使用微流体对3 d组织生物学和他是克拉罗斯诊断的创始人之一,该公司负责商业化mChip诊断平台。1。你花了多长时间开发这个芯片和你遇到了什么困难?我们在2002年开始工作当我和文森特·林德在哈佛博士后乔治·怀特赛兹教授的实验室。概念证明,即使一个已经工作的原则,一些健壮的领域需要的很大一部分聪明的工程和开发,在克拉罗斯诊断。2。有任何进一步的/更大的试验计划与当前设备?我们总是计划更多的试验,这两个版本发表在最近的研究以及其他版本。3所示。 How long do you expect it will take until this or similar devices will be used in practice in developing countries? If funding and resources were not constraining, we think we can get significant adoption within 2 years. 4. The reported sensitivity and specificity are very high. Could it also have benefits in the Western world? Yes. Claros Diagnostics has developed a prostate cancer monitoring test that can be used in portable settings. This version gained the CE Mark in 2010 (i.e. approval from European Union). 5. In what other diseases is the mChip applicable, any criteria a disease needs to meet? Will future versions be able to give quantitative results as well? The Claros version already provides quantitative results, so that is an ability this technology can already accomplish. We are limited to diseases with validated protein markers, but that includes many conditions, including infectious diseases, cancer, and many other conditions. In addition to this interview, here are two videos about the lab-on-a-chip technology: